Looking back at Trump’s tenure, and the potential implications of the US elections for pharma and the Affordable Health Act.

Introducing the fourth therapeutic class: live biotherapeutics – microorganisms isolated from the human gut with the potential to treat many diseases.

We speak with Laertis Ikonomou and Dan Weiss about the ISCT's work to combat unproven cell therapies.

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…

Joslin Diabetes Center researchers take the first steps towards an autologous cell therapy for obesity.

What's new in business?

New forays into the pharma space and a billion-dollar discovery deal… What’s new in business?

Researchers identify several factors associated with shorter marketing exclusivity periods.

How can small molecule "degraders" help target disease-causing proteins?

New method to control polymorphism could see “widespread use across the pharma industry”.